Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 191.36B |
| Revenue (ttm) | 43.89B |
| Net Income (ttm) | 10.86B |
| Shares Out | 1.94B |
| EPS (ttm) | 5.45 |
| PE Ratio | 18.15 |
| Forward PE | 14.36 |
| Dividend | 3.50 (3.54%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 2,916,689 |
| Average Volume | 2,335,620 |
| Open | 98.88 |
| Previous Close | 98.85 |
| Day's Range | 97.22 - 99.08 |
| 52-Week Range | 81.10 - 104.62 |
| Beta | 0.56 |
| RSI | 40.62 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Monte Rosa Therapeutics (GLUE) Soars on Novartis Collaboration
Monte Rosa Therapeutics (GLUE) Soars on Novartis Collaboration
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics Inc . (NASDAQ: GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro . Monte...
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.
Monte Rosa stock rises after pact with Novartis
Novartis (NVS) and Monte Rosa Partner to Advance Immune Disease Treatments
Novartis (NVS) and Monte Rosa Partner to Advance Immune Disease Treatments
Novartis signs up to US$5.7 billion licensing deal with Monte Rosa Therapeutics
Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to US$5.7 billion on Monday to develop drugs for immune-mediated diseases.
Novartis, Monte Rosa strike $5.7 billion drug development deal
Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.
Notable healthcare headlines for the week: Novo Nordisk, Novartis and UnitedHealth in focus
Novartis Catches a Sell. Goldman Sachs Says the Stock Is Overvalued.
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concerns
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concerns
Novartis cut to Sell at Goldman Sachs on near-term risks
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Novartis (NVS) Downgraded to Sell by Goldman Sachs | NVS Stock News
Novartis (NVS) Downgraded to Sell by Goldman Sachs | NVS Stock News
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action
Novartis Buys Tourmaline Bio in $1.4 Billion Heart Drug Deal(edit)
Novartis Buys Tourmaline Bio in $1.4 Billion Heart Drug Deal(edit)
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2233898979-7893e45faa544af5b04fdaf65f5136dd.jpg)
This Small Biotech Stock Is Surging Today. Here's Why.
Novartis said Tuesday it is buying Tourmaline Bio for $1.4 billion in a deal that gives the Swiss pharma giant access to the biotech’s late-stage cardiovascular drug pacibekitug.
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump 's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments , from...
Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling around 0.1% on Tuesday. Shares of Tourmaline Bio, Inc . (NASDAQ: TRML) rose sharply during Tuesday's session after the company announced it e...
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.
Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit
Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion. To...
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research. Novartis AG (NYSE: NVS) is up over ...
This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.
Novartis agrees to acquire Tourmaline Bio in an all-cash deal worth around $1.4 billion.
Novartis (NVS) to Acquire Tourmaline Bio in $1.4 Billion Deal
Novartis (NVS) to Acquire Tourmaline Bio in $1.4 Billion Deal
Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal
Nebius rockets after inking $17.4B deal with Microsoft. Novartis to acquire Tourmaline Bio in $1.4B all-cash deal. NFL's YouTube debut draws 17.3M viewers but rivals cry foul.